Authors: Carrascosa JM, Vilarrasa E, Belinchón I, Herranz P, Crespo J, Guimerá F, Olveira A; en representación del Grupo de Trabajo para el Abordaje Común de la Psoriasis y la EHmet (GACPE).
Actas Dermosifiliogr. 2023 Jan 28:S0001-7310(23)00056-X. doi: 10.1016/j.ad.2023.01.004. Online ahead of print.
Abstract
Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease (MAFLD). Not only is MALFD diagnosed more often in patients with psoriasis, but its clinical course is also more aggressive. A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis. Especially important is an analysis of risks and benefits of potentially hepatotoxic treatments. This consensus paper presents the recommendations of a group of experts in dermatology and hepatology regarding screening for MALFD as well as criteria for monitoring patients and referring them to hepatologists when liver disease is suspected.
Keywords: EHmet; Hepatotoxicity; MAFLD; Metabolic-associated fatty liver disease; Psoriasis; esteatosis hepática metabólica; hepatotoxicidad; psoriasis.
